Phase Forward to Present at World Drug Safety Congress Europe.
On Wednesday, September 16, from 1:30-2:00 p.m. local time, Robert Weber, principal consultant of Phase Forward's Lincoln Safety Group, will participate in stream session 2 titled "Post Marketing Safety Strategy." Mr. Weber's presentation will review the prioritization, tracking and management of signals from multiple sources, such as spontaneous adverse event reports, clinical studies and observational studies. In addition, Mr. Weber will discuss the importance of processes and integrated tools to deliver improved safety monitoring and risk management.
Phase Forward will also showcase its safety solutions, the Empirica[TM] Suite, which comprises the following products: Empirica Trace, Empirica Gateway, Empirica Signal and Empirica Study.
Members of the media interested in speaking with Mr. Weber and/or Phase Forward at the event should visit Phase Forward booth #7 or contact Maria Sumner at +44 1628 640743 or email@example.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 9, 2009|
|Previous Article:||hhgregg Announces Grand Opening of New Store in Evansville, IN.|
|Next Article:||Fitch Rates Agilent Technologies' Proposed $500MM Senior Unsecured Notes 'BBB'.|